Olmesartan Medoxomil/Amlodipine Rafarm (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil/amlodipine is indicated for hypertension, a condition managed through vascular resistance and fluid balance pathways.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension in patients uncontrolled on monotherapy: provides additional blood pressure reduction when an ARB alone is insufficient.
• Hypertension with concomitant edema risk: amlodipine’s vasodilatory effect counteracts fluid retention often seen with other antihypertensives.
• Hypertension in elderly patients: offers effective blood pressure control with a tolerable side‑effect profile.
• Hypertension with metabolic syndrome: assists in blood pressure management without adversely affecting glucose or lipid metabolism.

• Olmesartan medoxomil blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone‑mediated sodium retention. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combination produces additive blood‑pressure lowering effects by reducing peripheral resistance through two complementary mechanisms.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Peripheral edema: swelling of the ankles or feet.
• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially after standing.
• Flushing: transient warmth and redness of the skin.
• Fatigue: general feeling of tiredness.
• Nausea: occasional stomach upset.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of the face, lips, tongue, or throat.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Acute kidney injury: sudden reduction in kidney function.
• Myocardial infarction: rare occurrence of heart attack.
• Hyperkalemia: elevated potassium levels in the blood.

Before starting therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal impairment: assess kidney function and adjust dose if needed.
• Hepatic impairment: use with caution in patients with liver disease.
• Cardiovascular status: monitor for hypotension, especially in volume‑depleted patients.
• Pregnancy and lactation: contraindicated; avoid use during pregnancy.
• Drug‑specific monitoring: regular blood pressure checks and periodic laboratory tests.
• Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Olmesartan medoxil/amlodipine may interact with several drug classes; careful review is recommended.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade: concurrent use with ACE inhibitors or other ARBs increases risk of kidney injury and hyperkalemia.
• Strong CYP3A4 inhibitors: agents such as ketoconazole can raise amlodipine levels, leading to excessive hypotension.
• Lithium: co‑administration may raise lithium concentrations and precipitate toxicity.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate antihypertensive effect and cause orthostatic hypotension.\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response and affect renal function.
• Simvastatin: amlodipine increases its plasma concentration; dose adjustment may be needed.